Phase 3 trial

A large trial, usually in hundreds or thousands of people, done to confirm a drug works and is safe enough before it is licensed. Phase 1 and 2 trials are smaller and earlier.

Also called: phase iii, phase 3, phase 2, phase ii, phase 1, phase i

Related words randomised controlled trial

Topics Research

Questions people ask

How can I take part in a Crohn's clinical trial?

The NHS suggests asking your doctor or a patient organisation about trials you may be eligible for. You can also search the NIHR's Be Part of Research website for UK studies and contact research teams directly. Registries such as ISRCTN and ClinicalTrials.gov list studies and their results. Crohn's & Colitis UK explains how new medicines are tested before they are licensed.

Sources

How do I take part in Crohn's research?

Ask your IBD team whether your hospital is running any studies. You can also search the NIHR's Be Part of Research website, which lists UK studies currently recruiting people with Crohn's. The IBD BioResource invites people with Crohn's or colitis to join a national panel and be contacted about future studies. Crohn's & Colitis UK also lists ways to help shape research, such as patient and public involvement.

Sources

Can I have treatment for piles if I have Crohn's?

Piles can be treated, but surgery needs care. A 2022 review of studies on piles surgery in people with IBD found the evidence was low quality and concluded that operations in Crohn's should be done cautiously, after other treatments have failed and when the disease is inactive. The NHS describes self-care and pharmacy options for piles; talk to your IBD team before any procedure.

Sources

What is a Cochrane review and why does it matter?

Cochrane reviews are systematic reviews: researchers find every good trial on a question, judge how reliable each one is and combine the results. They also grade how certain the evidence is. For Crohn's, Cochrane has found strong evidence for some treatments, such as vedolizumab, and too little evidence to judge others, such as treatments for fatigue.

Sources

Where to read more

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

The Lancet Study May 2022 Patients and professionals

Two trials testing risankizumab (Skyrizi) drips to bring active Crohn's under control, including in people for whom other biologics had failed. Risankizumab led to more remissions, and more improvement seen on camera tests of the bowel, at 12 weeks than placebo, and was generally well tolerated.

Topics Biologics and newer medicines

Jargon explained induction phase 3 trial endoscopic response

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

The Lancet Study Dec 2017 Patients and professionals

CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.

Topics Monitoring Biologics and newer medicines Research

Jargon explained tight control faecal calprotectin CRP mucosal healing treat to target

Clinical trials

NHS Web page Dec 2022 For patients

The NHS explains what a clinical trial is and how to find one. It suggests asking your doctor or a patient organisation, and points to the Be Part of Research website, where you can search UK studies and contact researchers.

Topics Research

Jargon explained clinical trial randomised

Be Part of Research

NIHR Tool For patients

The NHS research service's search tool for finding health studies to take part in across the UK. Searching for Crohn's disease lists studies currently recruiting, with who can join and where. A good first stop if you want to volunteer for a trial.

Topics Research

Jargon explained clinical trial recruiting

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

The Lancet Systematic review Dec 2017 For professionals

A review of population studies from around the world. In Western countries the number of new cases is levelling off but more than 0.3% of people now live with IBD. In newly industrialised countries in Asia, Africa and South America, new cases are rising quickly as lifestyles become more Western.

Topics About Crohn's disease Research

Jargon explained systematic review incidence prevalence population-based study

Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC)

New England Journal of Medicine Study Apr 2010 Patients and professionals

A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.

Topics Biologics and newer medicines Immunosuppressants Research

Jargon explained combination therapy steroid-free remission mucosal healing randomised controlled trial

ISRCTN Registry

ISRCTN Tool Patients and professionals

A WHO-recognised registry where UK and international studies are recorded before they start, with their aims and progress. You can search it free for Crohn's studies, including UK trials such as PROFILE. Records are written for researchers, so they can be technical.

Topics Research

Jargon explained trial registry study protocol ISRCTN number

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Gastroenterology Study Jan 2007 Patients and professionals

The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.

Topics Biologics and newer medicines

Jargon explained maintenance remission CDAI placebo

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

The Lancet Study May 2002 Patients and professionals

This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.

Topics Biologics and newer medicines Research

Jargon explained maintenance therapy remission placebo

Treatments for extreme tiredness and lack of energy (fatigue) in inflammatory bowel disease

Cochrane Systematic review Apr 2020 Patients and professionals

A Cochrane review of 14 studies, covering both drug and non-drug treatments such as exercise and psychological approaches, for fatigue in IBD. The reviewers concluded the evidence is too uncertain to say which treatments work and called for trials designed specifically around fatigue.

Topics Fatigue Research

Jargon explained fatigue systematic review

Search everything for "phase 3 trial"